RVTY

In a comparison of two Medical Services sector stocks, Elevance Health (ELV) emerges as the better value opportunity compared to Revvity (RVTY). ELV holds a Zacks Rank of #2 (Buy) with a Value grade of A, supported by a lower forward P/E ratio of 16.37 and a PEG ratio of 2.32. RVTY, ranked #3 (Hold) with a Value grade of C, has a higher forward P/E of 29.35 and PEG ratio of 2.86, making it less attractive to value investors.

Revvity announced the launch of Signals LabGistics, an AI-first software solution designed to connect and orchestrate scientific workflows across pharmaceutical, biotechnology, and specialty chemical companies. The platform converts natural-language instructions into coordinated workflows, integrates with existing lab systems, and will be available in major markets by December 2026. The announcement follows Revvity's recent acquisitions and product launches in diabetes screening and cell models.

Revvity (RVTY), a maker of scientific instruments, has been upgraded to Zacks Rank #2 (Buy) due to rising earnings estimate revisions over the past three months. The upgrade reflects positive momentum in the company's earnings outlook, which historically correlates with near-term stock price increases. The company is expected to earn $5.36 per share for fiscal year 2026.

Revvity (RVTY) is rated a Hold with strong growth potential across diagnostics, life sciences, and scientific informatics. The company benefits from AI-driven demand, the planned Human Cell Design acquisition, and solid diagnostics growth (11% organic revenue increase in Q2).

However, challenges include China divestiture uncertainty, uneven academic funding, and margin pressure from non-recurring tariff benefits. The stock has outperformed the broader market with a 56.1% year-to-date gain.

IDEXX Laboratories is set to report Q3 2026 results on November 2, with consensus estimates projecting 7.5% revenue growth to $1.19 billion and 9.1% EPS growth to $3.71. The company's Companion Animal Group diagnostics, Water segment, and Livestock/Poultry/Dairy divisions are expected to drive performance, supported by volume growth and recurring revenues. IDEXX carries a Zacks Rank #2 with a +0.59% Earnings ESP, suggesting potential to beat estimates.

Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion.

The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies.

Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.